Evidence mapPaperPMID 36540004Full record

ReviewJournal of diabetes science and technology2023

Factors Affecting Performance of Insulin Pen Injector Technology: A Narrative Review.

Thomas Sparre, Laura Hammershøy, Dorte Bjerre Steensgaard, Jeppe Sturis, Per Vikkelsøe, Antonino Azzarello

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of diabetes science and technology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Thomas SparreNovo Nordisk A/S, Søborg, Denmark.ORCID 0000-0002-1441-0727
Laura HammershøyNovo Nordisk A/S, Hillerød, Denmark.
Dorte Bjerre SteensgaardNovo Nordisk A/S, Måløv, Denmark.
Jeppe SturisNovo Nordisk A/S, Måløv, Denmark.
Per VikkelsøeNovo Nordisk A/S, Hillerød, Denmark.
Antonino AzzarelloNovo Nordisk A/S, Søborg, Denmark.
Novo Nordisk (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInsulin treatment is an essential hormone replacement therapy for the survival of people with type 1 diabetes and is often used for treatment in type 2 diabetes, particularly as the disease progresses. Advances in insulin therapy have been made since its discovery, including production of human insulin and development of insulin analogs with improved efficacy and safety profiles. The different types of available insulin formulations allow health care professionals to personalize treatment to an individual's needs. Generally, insulin requires parenteral administration via subcutaneous injection owing to very low oral bioavailability.

methodsThis article reviews the human, technological, economical, and regulatory factors affecting the performance of insulin pens and the relationship between them. Opportunities and challenges that insulin pen injections may encounter in the future are also considered.

resultsInsulin delivery devices, together with other factors, influence dose accuracy, convenience, and quality of life, contributing to easier medication administration with high efficacy and safety. For patients, ease of use, fast and accurate drug delivery, and painless injection are the most valuable features of an insulin injection device. For manufacturers, technological feasibility and economic viability also need to be considered when developing injection devices.

conclusionInsulin pen injectors are generally preferred over vial and syringe, although access may be limited in some health care systems. Insulin pen injectors can adapt to different insulin regimens and formulations and have the potential to acquire dosing data in real time.

Indexed as

Diabetes Mellitus, Type 2InsulinHumansHypoglycemic AgentsInjections, SubcutaneousInsulin, Regular, HumanQuality of LifeSyringesHypoglycemic AgentsInsulinInsulin, Regular, Humandiabetesinjection deviceinsulin penperformance

Identifiers

PMID36540004
PMCPMC10012375
OpenAlexW4312066738

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.